Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD86 CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Ludwig Maximilian University of Munich
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD86 CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target Cluster of Differentiation 86 (CD86), also known as B7-2. CD86 was identified as a promising target for acute myeloid leukemia (AML) through high-resolution single-cell RNA sequencing, which revealed its high expression on AML blasts and leukemic stem cells compared to healthy tissues and hematopoietic stem cells. Developed by researchers at Ludwig-Maximilians-Universität (LMU) Munich and the Helmholtz Centre Munich, these CAR-T cells have demonstrated potent anti-leukemic efficacy in preclinical in vitro and in vivo models, including patient-derived xenografts (PDX). The therapy aims to provide a safe and effective treatment option for AML, a disease where finding specific targets that spare healthy cells has been challenging.
- Other names
- anti-CD86 CAR-T cellsanti-CD-86 CAR-T cellsanti-CD 86 CAR-T cellsCD86-targeted CAR-T cellsCD-86-targeted CAR-T cellsCD 86-targeted CAR-T cells
02
Targets
CD86 (T-lymphocyte activation antigen CD86)
Beyond the preview
Go deeper on CD86 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD86 CAR-T cells.